凯赛生物
(688065)
| 流通市值：267.65亿 | | | 总市值：330.93亿 |
| 流通股本：5.83亿 | | | 总股本：7.21亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,545,040,722.5 | 1,670,767,942.21 | 775,769,935.75 | 2,957,911,554.76 |
| 营业收入 | 2,545,040,722.5 | 1,670,767,942.21 | 775,769,935.75 | 2,957,911,554.76 |
| 二、营业总成本 | 1,946,642,190.87 | 1,283,596,878.98 | 619,368,581.39 | 2,361,273,032.48 |
| 营业成本 | 1,660,528,993.42 | 1,105,270,854.11 | 514,850,598.38 | 2,033,666,835.61 |
| 税金及附加 | 26,910,896.27 | 18,658,927.33 | 9,240,459.11 | 35,788,319.56 |
| 销售费用 | 44,514,491.83 | 29,289,681.12 | 13,641,726.22 | 54,576,731.49 |
| 管理费用 | 135,108,618.75 | 90,894,858.67 | 43,022,810.13 | 167,912,474.07 |
| 研发费用 | 178,566,777.26 | 123,198,537.35 | 60,550,596.03 | 233,339,322.82 |
| 财务费用 | -98,987,586.66 | -83,715,979.6 | -21,937,608.48 | -164,010,651.07 |
| 其中:利息费用 | 8,694,865.96 | 7,746,055.43 | 7,000,087.54 | 27,433,126.5 |
| 其中:利息收入 | 142,367,522.4 | 98,008,050.86 | 31,187,657.19 | 160,754,505.67 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 5,657,569.11 | 2,172,228.69 | - | - |
| 加:投资收益 | -4,222,426.2 | -5,951,887.58 | -2,616,095.56 | -8,951,802.66 |
| 资产处置收益 | 6,717,488.5 | 5,194,901.42 | -288.89 | 403,263.87 |
| 资产减值损失(新) | -114,070,263.31 | -57,703,425.03 | -782,080.26 | -87,320,261.39 |
| 信用减值损失(新) | -15,653,816.42 | -6,894,765.82 | -4,394,492.06 | -3,340,568.52 |
| 其他收益 | 30,116,825.37 | 21,776,292.03 | 13,077,303.18 | 54,132,018.03 |
| 四、营业利润 | 506,943,908.68 | 345,764,406.94 | 161,685,700.77 | 551,561,171.61 |
| 加:营业外收入 | 590,321.17 | 449,569.69 | 346,639.34 | 1,041,438.05 |
| 减:营业外支出 | 4,114,750.58 | 4,101,537.05 | 3,991,451.1 | 4,587,380.63 |
| 五、利润总额 | 503,419,479.27 | 342,112,439.58 | 158,040,889.01 | 548,015,229.03 |
| 减:所得税费用 | 80,514,760.05 | 57,920,668.2 | 33,722,197.09 | 73,425,897.36 |
| 六、净利润 | 422,904,719.22 | 284,191,771.38 | 124,318,691.92 | 474,589,331.67 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 422,904,719.22 | 284,191,771.38 | 124,318,691.92 | 474,589,331.67 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 450,673,830.55 | 308,667,050.28 | 136,950,113.57 | 488,961,919.11 |
| 少数股东损益 | -27,769,111.33 | -24,475,278.9 | -12,631,421.65 | -14,372,587.44 |
| 扣除非经常损益后的净利润 | 428,560,042.97 | 296,452,653.46 | 135,362,505.06 | 464,730,541.23 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.67 | 0.47 | 0.23 | 0.84 |
| (二)稀释每股收益 | 0.67 | 0.47 | 0.23 | 0.84 |
| 八、其他综合收益 | 4,490,569.41 | 4,035,669.85 | 3,862,477.8 | -5,486,780.85 |
| 归属于母公司股东的其他综合收益 | 4,490,569.41 | 4,035,669.85 | 3,862,477.8 | -5,486,780.85 |
| 九、综合收益总额 | 427,395,288.63 | 288,227,441.23 | 128,181,169.72 | 469,102,550.82 |
| 归属于母公司股东的综合收益总额 | 455,164,399.96 | 312,702,720.13 | 140,812,591.37 | 483,475,138.26 |
| 归属于少数股东的综合收益总额 | -27,769,111.33 | -24,475,278.9 | -12,631,421.65 | -14,372,587.44 |
| 公告日期 | 2025-10-31 | 2025-08-16 | 2025-04-30 | 2025-04-22 |
| 审计意见(境内) | | | | 标准无保留意见 |